Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Investig Drugs. 2007 Feb;8(2):159-67.

Drug evaluation: DNA/MVA prime-boost HIV vaccine.

Author information

  • 1University of Melbourne, Department of Microbiology and Immunology, Melbourne, Victoria 3010, Australia. skent@unimelb.edu.au

Abstract

Oxford University and Nairobi University are jointly developing a HIVA.DNA/modified vaccinia Ankara (MVA) prime-boost vaccine for the potential prevention of infection with HIV subtype A. The vaccination strategy consists of priming with a DNA vaccine made from HIV-1 clade A gag p24/p17 consensus sequence (pTHr.HIVA) then boosting with a MVA virus expressing HIVA (MVA.HIVA). Phase II clinical trials of the vaccine are underway in Kenya and the UK.

PMID:
17328232
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk